key: cord-0719483-0zphhxxh
authors: Robertson, L. J.; Moore, J. S.; Blighe, K.; Ng, K. Y.; Quinn, N.; Jennings, F.; Warnock, G.; Sharpe, P.; Clarke, M.; Maguire, K.; Rainey, S.; Price, R.; Burns, W.; Kowalczyk, A.; Awuah, A.; McNamee, S.; Wallace, G.; Sager, S.; Chao Shern, C.; Nesbit, M. A.; McLaughlin, J.; Moore, T.
title: SARS-CoV-2 antibody testing in a UK population: detectable IgG for up to 20 weeks post infection.
date: 2020-10-01
journal: nan
DOI: 10.1101/2020.09.29.20201509
sha: 6a08977cca603955cb4acaf30bc667ea5ad58385
doc_id: 719483
cord_uid: 0zphhxxh

Background The SARS-CoV-2 pandemic necessitated rapid and global responses across all areas of healthcare, including an unprecedented interest in serological immunoassays to detect antibodies to the virus. The dynamics of the immune response to SARS-CoV-2 is still not well understood. Methods We measure SARS-CoV-2 antibody levels in plasma samples from 880 people in Northern Ireland by Roche Elecsys Anti-SARS-CoV-2 IgG/IgA/IgM, Abbott SARS-CoV-2 IgG and EuroImmun IgG SARS-CoV-2 ELISA immunoassays to analyse immune dynamics over time. Using these results, we develop a "pseudo gold standard" reference cohort against which to assess immunoassay performance. We report performance metrics for the UK-RTC AbC-19 rapid lateral flow immunoassay (LFIA) against a characterised panel of 304 positives established using the "pseudo gold standard" system and 350 negative samples. Results We detect persistence of SARS-CoV-2 IgG up to 140 days (20 weeks) post infection, across all three antibody immunoassays, at levels up to 4.4 times the cut-off for a positive result by Roche measurement. Using our "pseudo gold standard" cohort (n=348 positive, n=510 negative) we determine the sensitivity and specificity of the three commercial immunoassays used (EuroImmun; Sens. 98.9% [97.7-99.7%]; Spec. 99.2% [98.4-99.8%]; Roche; Sens. 99.4% [98.6-100%]; Spec. (96.7% [95.1-98.2%]; Abbott; Sens. 86.8% [83.1-90.2%]; Spec. (99.2% [98.4-99.8%]). The UK-RTC AbC-19 lateral flow immunoassay using shows a sensitivity of 97.70% (95.72%-99.34%) and specificity of 100% (100.00-100.00%). Conclusions Through comprehensive analysis of a large cohort of pre-pandemic and pandemic individuals, we show detectable levels of IgG antibodies, lasting up to 140 days, providing insight to immunity levels at later time points. We propose an alternative to RT-PCR positive status as a standard for assessing SARS-CoV-2 antibody assays and show strong performance metrics for the AbC-19 rapid test.

RNA detection (RT-qPCR assays), to detect acute infection 3 . RT-qPCR assays are labour and reagent intensive, limited by a short temporal window for positive diagnosis, and exhibit potential for false negative results 4 . Evidence suggests sensitivity of RT-qPCR can be as low as 70% 5 . Lockdown measures and "flattening the curve" strategies meant many infected individuals were instructed to self-isolate and were not offered a diagnostic RT-qPCR, with much of the testing limited to patients admitted to hospital, who perhaps reflect a more severely infected cohort. Consequently, a potentially large number of cases were unconfirmed or undetected 6 .

The ability to accurately detect SARS-CoV-2 specific antibodies, which develop after an immune response is evoked, is vital for building biobanks of convalescent sera for treatment, monitoring immune response to infection and assessing responses to vaccination programmes. Knowledge of antibody levels, indicative of prior virus exposure, will play an important role in public health policy and understanding SARS-CoV-2 epidemiology, including determining seroprevalence. Knowledge of the timing for when antibody levels can be measured is essential to allow accurate reporting.

Commercial serology immunoassays are mostly laboratory-based and measure IgG antibody levels in plasma or serum. Alternatively, lateral flow immunoassays (LFIAs), require a finger prick blood sample and can be used at point-of-care (POC) or in the home; particularly important in the context of lockdown enforcement during the pandemic. Currently, a limited number of laboratory-based chemiluminescence

The complexities of the humoral immune response to SARS-CoV-2 is a much-debated topic. The 'sero-silent', those who do not make IgG, may remain asymptomatic or conversely may become particularly unwell and unfortunately die 7 

IgG against different antigenic regions of the virus such as the spike or nucleocapsid protein. Patients who remain asymptomatic may mount a humoral immune response which is short-lived, with detectable levels of antibody falling after 2 months 8 . This, alongside potentially low sensitivity and lack of RT-PCR test availability across the UK has hindered development of well characterised serology samples known to contain IgG antibodies to SARS-CoV-2.

Herein, we describe use of Roche and Abbott commercial immunoassays, as well as the EuroImmun Anti-SARS-CoV-2 ELISA-IgG against the S1 domain of the spike antigenic protein of SARS-CoV-2 (EuroImmun UK, London, UK) to characterise a large number (880) of pre-pandemic and pandemic COVID-19 blood samples from within Northern Ireland and report on longevity of IgG antibodies detected. Presently, there is no gold standard assay for comparison. Therefore, we describe a 'pseudo gold-standard' against which to evaluate assays. Furthermore, we present results of an independent validation of the UK-RTC AbC-19 POC LFIA against a cohort of 304 known positives according to this 'pseudo gold-standard' system and 350 known negative samples for IgG to SARS-CoV-2.

This study was approved by Ulster University Institutional Ethics committee (REC/20/0043), South Birmingham REC (The PANDEMIC Study IRAS Project All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 1, 2020. . https://doi.org/10.1101/2020.09.29.20201509 doi: medRxiv preprint ID: 286041Ref 20/WM/0184) and adhered to the Declaration of Helsinki and Good Clinical Practice.

The flow of participant samples is summarised in Figure S1 . All participants provided informed consent with no adverse events. An online recruitment strategy was employed, with the study advertised through internal Ulster University email, website and social media. A BBC Newsline feature providing the pandemic study email address also prompted interest from the general population.

The first 800 respondents who expressed interest were provided with an online patient information sheet, consent form and health questionnaire and invited to register to attend a clinic. Exclusion criteria related to blood disorder or contraindication to giving a blood sample. To enrich the cohort for positive samples, further participants were invited if they had previously tested PCR positive or had the distinctive symptom of loss of taste and smell. Blood sampling clinics were held at locations around Northern Ireland between April and July 2020 resulting in collection of 263 10ml EDTA plasma samples from 263 separate study participants. A small cohort (n=19) of anonymised plasma samples were obtained from Avellino, USA. Additional anonymised plasma samples were obtained from Southern Health and Social Care Trust (SHSCT) (n= 200, more than 3 years old). Plasma samples were used at no more than 3 freezethaw cycles for all analyses reported within this manuscript.

Basic demographic information and data about positive RT-PCR result and time from symptom onset was provided by PANDEMIC study participants through the secure online questionnaire. Anonymised participant samples from USA, SHSCT and NIBTS were provided with age, gender and time since PCR-positive, where a previous test had been carried out.

Details of laboratory immunoassays are summarised in supplementary methods and Table S1 .

UK-RTC AbC-19 POC LFIA testing was conducted at Ulster University according to manufacturer's instructions (details in Table S1 ). Assays were performed as cohorts, with samples in batches of 10, with one researcher adding 2.5µL of plasma to the assay and a second adding 100µL of buffer immediately following sample addition.

After 20 minutes, the strength of each resulting test line was scored from 0-10 according to a visual score card (scored by 3 researchers; Figure S2 ). A score ³1 is positive. Details of samples for analytical specificity and sensitivity analysis are available in Supplementary methods.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 1, 2020. To define a gold-standard, a positive result was determined as any individual who was positive by 2 out of 3 immunoassays, while negative was defined as negative by 2 out of 3 immunoassays. EuroImmun Borderline results were excluded. Sensitivity, specificity, and accuracy were then derived via the pROC package, with 95% confidence intervals produced after 2000 bootstraps. ROC analysis was performed via the pROC package. To compare test result (Positive|Negative) to age, a binary logistic regression model was produced with test result as outcome -a p-value was then derived via χ 2 ANOVA. To compare time against test result (encoded continuously), a linear regression was performed. We calculated median per time-All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 1, 2020. . https://doi.org/10.1101/2020.09.29.20201509 doi: medRxiv preprint period and then converted these to log [base 2] ratios against the positivity cut-off for each assay. All plots were generated via ggplot2 or custom functions using base R 12 .

Antibody levels in plasma from 880 individuals were assessed using the three SARS-CoV-2 immunoassays; EuroImmun IgG, Roche Elecsys IgG/IgM/IgA and Abbott Architect IgG (Table S1 ). This included a negative cohort of 223 pre-pandemic plasma Figure S3 , p<0.0001). When segregated by age group, however, differences were less apparent in certain groups ( Figure S4 ).

Excluding the pre-pandemic cohort, this gap reduced but remained statistically All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Of note, out of 265 individuals with a previous positive RT-PCR result, 14 (5.2%) did not show any detectable antibodies by all three immunoassays, with no association with age, gender or time between test and blood draw (data not shown).

The three commercial laboratory immunoassays provide a ratio value that increases with IgG antibody titre. When correlation between these values is assessed, good overall agreement is observed between the three immunoassays ( Figure 1 , Figure   S5 perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 1, 2020. . https://doi.org/10.1101/2020.09.29.20201509 doi: medRxiv preprint

Use of a previous positive RT-PCR for SARS-CoV-2 viral RNA as a gold standard for the presence of IgG has limitations, therefore we developed a 'pseudo gold-standard' based on laboratory immunoassay antibody results, in which a positive result by two or more immunoassays classes a sample as antibody positive (n=348), whilst a negative result on two or more immunoassays classes a sample as negative (n=510).

EuroImmun borderline results were excluded from this analysis (n=22 (Figure 3 ).

Using the commercial immunoassays described we established a well characterised serology sample set of 'known positive' and 'known negative' for IgG antibodies to SARS-CoV-2 to evaluate performance metrics for the UK-RTC AbC-19 Rapid POC LFIA.

This LFIA detects IgG antibodies against the spike protein antigen, so we therefore required all samples to be positive by the EuroImmun SARS-CoV-2 IgG ELISA, which likewise detects antibodies against the S1 domain 14 . In line with our 'pseudo gold standard' system, samples were also required to be positive by a second All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 1, 2020. . https://doi.org/10.1101/2020.09.29.20201509 doi: medRxiv preprint immunoassay (Roche or Abbott). To analyse specificity, we assessed 350 plasma samples from participants classed as 'known negative' on the AbC-19 LFIA. All samples were from individuals confirmed to be negative across all three laboratory assays (Roche, EuroImmun, Abbott). Using these positive n= 304 and negative n=350 antibody cohorts, we determined a sensitivity of 97.70% (95.72%-99.34%) and specificity of 100% (100.00-100.00%) for the AbC-19 LFIA (Table 1) .

When used as intended in POC settings, the AbC-19 LFIA provides binary positive/negative results. However, when assessing LFIA in the laboratory, each test line was scored against the scorecard by three independent researchers (0 negative, 1-10 positive; Figure S2 ). Compared to quantitative outputs from the Abbott, Figure 4 , Figure S5 ).

We observed no cross-reactivity across samples with known H5N1 influenza, Respiratory syncytial virus, Influenza A, Influenza B, Bordetella Pertussis, Haemophilus Influenzae, Seasonal coronavirus NL63 and 229E on the AbC-19 LFIA.

(n=34 samples, n=8 distinct respiratory viruses; Table S3 ). Against a panel of external reference SARS-CoV-2 serology sample, the AbC-19 LFIA detected antibodies with scores commensurate to the EuroImmun ELISA scores ( Figure S6 , Table S4 ).

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 1, 2020. . https://doi.org/10.1101/2020.09.29.20201509 doi: medRxiv preprint Serological antibody immunoassays are an important tool in helping combat the SARS-CoV-2 pandemic. One difficulty faced in validation of antibody diagnostic assays has been access to samples with known SARS-CoV-2 antibody status. As previously described, there is no clear gold standard for reference against which to assess SARS-CoV-2 immunoassays. A positive RT-PCR test has been used previously as a reference standard, although limited by a high rate of false negatives, failure in some cases to develop IgG antibodies (sero-silence or lack of antibody against the same antigenic component of the virus as the immunoassay uses as a capture antigen), or the lack of RT-PCR testing availability early in the pandemic 3,5,15 .

Self-assessment of symptoms for COVID-19 disease is a poor indicator of previous infection, even among healthcare workers 16 antibodies decline at 90 days, we also noted a statistically significant decline over time but levels remain detectable at 140 days ( Figure 2 ). We note that IgG levels reach their peak as late as Week 8-12 (Roche ratio 5.45 times threshold cut-off) 18 , though this may be an artefact of lower number of participants at earlier timepoints All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 1, 2020. . https://doi.org/10.1101/2020.09.29.20201509 doi: medRxiv preprint (Figure 2d ). Longitudinal studies on SARS-CoV convalescent patients suggests that detectable IgG can still be present as long as 2 years after infection 20 . Further studies are needed on large cohorts with sequential antibody immunoassays performed on symptomatic and non-symptomatic individuals as well as those with mild and severe COVID-19. This is vital to inform vaccine durability, so-called 'immune passports' and in the definition of a protective threshold for anti-SARS-CoV-2 antibodies. This broader detection window supports the use of these immunoassays for seroprevalence screening 19 .

To assess sensitivity and specificity, we developed a 'pseudo gold-standard' against which to analyse assays, which does not rely on a single test as reference. A similar approach was used in a recent seroprevalence study in Iceland, whereby two positive antibody results were required to determine a participant positive 15 . The sensitivity and specificity we observed for these laboratory immunoassays did not differ greatly from Public Health England evaluations, though EuroImmun performed with higher sensitivity (98.9%) than the reported 72% and Abbott with lower (86.8%) than the reported 92.7% [21] [22] [23] .

Our evaluation of performance metrics for the rapid POC finger-prick AbC-19 LFIA gave 97.7% sensitivity and 100% specificity. Strong correlation was observed in quantitative score between results on all immunoassays with the highest observed between EuroImmun and AbC-19 LFIA ( Figure S5 ). This is to be expected, given both the AbC-19 LFIA and EuroImmun ELISA detect antibodies against spike protein. For the assessment of immunity to prior natural infection as well as to immunisation, it is important to note IgG antibodies against SARS-CoV-2 spike protein detected by All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 1, 2020. . https://doi.org/10.1101/2020.09.29.20201509 doi: medRxiv preprint laboratory-based EuroImmun ELISA and AbC-19 POC LFIA are known to correlate with neutralizing antibodies, which may confer future immunity 24,25 .

The 'pseudo gold-standard' system may artificially raise the threshold for positive sample inclusion, by requiring a positive result by two immunoassays. However, similar issues have been raised when using previous RT-PCR result or definitive COVID-19 symptoms as inclusion criteria given these will likely skew a cohort towards more severe disease, which may increase immune response 5 . In the absence of a clear gold standard test, our 'pseudo-gold standard' system relies on no single test and instead takes an average of three. We observed a high number of positive participants in our cohorts (n=348; 40.9%), a reflection of biases in the recruitment methods, enriching for positive samples.

The validation of the AbC-19 LFIA reported excellent performance metrics and we note it uses plasma from venous blood samples, as opposed to the use of a finger prick blood sample. A matrix study comparing the result from finger prick blood versus plasma is under investigation by this PANDEMIC Study team @Ulster University.

When this LFIA was used on our cohort, a number of the positive results scored low, 1/10 (using the score card under laboratory conditions) with a faint test band, visible to a trained laboratory scientist but perhaps difficult to identify as positive by the general public conducting a self-test ( Figure S6 ). This faint line may be reflective of the longer time from infection. If this AbC-19 LFIA is to be rolled out as a home-testing kit, it is important to determine if members of the public observe the same results as observed in the laboratory. Again, this is the aim of an ongoing usability study by the PANDEMIC study team @Ulster University. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 1, 2020. . https://doi.org/10.1101/2020.09.29.20201509 doi: medRxiv preprint Lastly, it is important to consider prevalence when interpreting an assays' sensitivity and specificity as in a low prevalence scenario, as even slightly lowered performance metrics (such as the MHRA required 98%) can result in large numbers of false negative and false positive results 10, 26 

At the time of this study TM and JML acted as advisors to CIGA HealthCare, an industrial partner in the UK Rapid Test Consortium. No personal financial reward or All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 1, 2020. . https://doi.org/10.1101/2020.09.29.20201509 doi: medRxiv preprint renumeration was received for this advisory role. At the time of submission of this manuscript TM and JML no longer held these advisory positions.

All other authors have no potential conflict of interest to report.

Funding for this study was obtained from UK-RTC to cover all laboratory costs incurred.

IgG__1_.pdf.

Public April 2020. 2020 https://www.gov.uk/government/publications/spi-b-preempting-possible-negative-behavioural-responses-to-covid-19-antibodytesting-13-april-2020.

All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted October 1, 2020. . https://doi.org/10.1101/2020.09.29.20201509 doi: medRxiv preprint preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted October 1, 2020. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 1, 2020. All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted October 1, 2020. . https://doi.org/10.1101/2020.09.29.20201509 doi: medRxiv preprint EuroImmun (red), Roche (maroon), Abbott (blue). The AUC for each test is close to 1, indicating the immunoassays perform with a high level of accuracy. Diagonal grey line is the reference line (AUC=0.5).

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 1, 2020. . https://doi.org/10.1101/2020.09.29.20201509 doi: medRxiv preprint perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 1, 2020. . https://doi.org/10.1101/2020.09.29.20201509 doi: medRxiv preprint

Rolling updates on coronavirus disease (COVID-19)

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Developing antibody tests for SARS-CoV-2

Negative nasopharyngeal and oropharyngeal swabs do not rule out COVID-19

COVID-19 herd immunity in the Brazilian Amazon

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Biostatistics : a foundation for analysis in the health sciences

Medicines and Healthcare product Regulatory Agency. Target product profile: antibody tests to help determine if people have immunity to SARS-CoV-2

The R Development Core Team. R: A language and environment for statistical computing

ggplot2 Elegant Graphics for Data Analysis

Testing for responses to the wrong SARS-CoV-2 antigen?

Self assessment overestimates historical COVID-19 disease relative to sensitive serological assays: cross sectional study in UK key workers

Living on Three Time Scales: The Dynamics of Plasma Cell and Antibody Populations Illustrated for Hepatitis A Virus

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Antibody tests for identification of current and past infection with SARS-CoV-2

Duration of antibody responses after severe acute respiratory syndrome

Evaluation of the Abbott SARS-CoV-2 IgG for the detection of anti-SARSCoV-2 antibodies